SOPHiA GENETICS (NASDAQ:SOPH) CTO Sells $38,261.44 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 6,944 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $5.51, for a total value of $38,261.44. Following the completion of the transaction, the chief technology officer directly owned 197,456 shares in the company, valued at $1,087,982.56. This trade represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

• On Tuesday, April 7th, Abhimanyu Verma sold 1,030 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total value of $5,016.10.
• On Monday, April 6th, Abhimanyu Verma sold 2,519 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.86, for a total value of $12,242.34.

SOPHiA GENETICS Trading Up 1.1%

NASDAQ:SOPH traded up $0.06 on Friday, hitting $5.75. 423,880 shares of the stock were exchanged, compared to its average volume of 174,550. The stock has a market cap of $482.37 million, a PE ratio of -11.06 and a beta of 0.98. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. The stock has a fifty day moving average of $5.06 and a 200-day moving average of $4.92. SOPHiA GENETICS SA has a fifty-two week low of $2.81 and a fifty-two week high of $5.94.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The firm had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Analysts Set New Price Targets

Several research analysts recently commented on SOPH shares. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. BTIG Research reiterated a “buy” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $7.50.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC boosted its position in shares of SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after buying an additional 1,481,636 shares during the period. Principal Financial Group Inc. boosted its position in shares of SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after buying an additional 9,800 shares during the period. Archon Capital Management LLC grew its stake in shares of SOPHiA GENETICS by 3.4% in the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock valued at $2,061,000 after buying an additional 14,342 shares in the last quarter. Finally, Hodges Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS in the first quarter valued at about $2,157,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.